Although preclinical and clinical trials have shown that PARP inhibitors are effective for BRCA1-associated cancers, some limitations to the synthetic lethality approach still exist, such as evidence for therapeutic efficacy, side effects, and resistance to PARP inhibitors. Here, BRCA1 is linked to cancer.